Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Comparative Cost-Efficiency Analysis of Trilaciclib, a Novel CDK4/6 Inhibitor, in the Prophylaxis of Chemotherapy-Induced Myelosuppression

Nicholas Guy Little, Ali McBride, Nicole Henry, Karen MacDonald, Ivo Abraham

Blood (2021) 138 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2021-146935

Published: 2021

Journal Articles

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-142749

Published: 2020

Journal Articles

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136810

Published: 2020

Journal Articles

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Ali McBride, PharmD, MS, Sanjeev Balu, PhD, Kim Campbell, PharmD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2018-99-113283

Published: 2018

Journal Articles

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Ali McBride, PharmD,MS, Andriy Krendyukov, MD MBA, Nicola Mathieson, Kim Campbell, PharmD, Sanjeev Balu, PhD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2018-99-116315

Published: 2018

Journal Articles

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Ali McBride, PharmD,MS, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, PhD RN, Sanjeev Balu

Blood (2017) 130 (Supplement 1): 3380.

https://doi.org/10.1182/blood.V130.Suppl_1.3380.3380

Published: 2017

Journal Articles

Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia: Meta-Analyses of Prevalence Rates By Measurement Method

Ziyad Alrabiah, PharmD, BCPS, Abdulaziz Alhossan, PharmD, BCPS, Seongseok Yun, MD PhD, Karen MacDonald, PhD, Ivo Abraham, PhD

Blood (2016) 128 (22): 3610.

https://doi.org/10.1182/blood.V128.22.3610.3610

Published: 2016

Journal Articles

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

Reem Diri, PharmD, Ali McBride, PharmD,MS, Christopher Lee, PhD, Alaa Bagalagel, PharmD, Hussain Bakhsh, PharmD, Daniel O. Persky, MD, Karen MacDonald, PhD, Jennifer Martin, MA, Ivo Abraham, PhD

Blood (2015) 126 (23): 4764.

https://doi.org/10.1182/blood.V126.23.4764.4764

Published: 2015

Journal Articles

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Lucien Noens, Marie-Anne van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald, Sabina De Geest, Tara Albrecht, Ivo Abraham

Blood (2009) 113 (22): 5401–5411.

https://doi.org/10.1182/blood-2008-12-196543

Published: 2009

Journal Articles

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Carsten Bokemeyer, Pierre Soubeyran, Matti Aapro, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4706.

https://doi.org/10.1182/blood.V112.11.4706.4706

Published: 2008

Journal Articles

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Pierre Soubeyran, Matti Aapro, Carsten Bokemeyer, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4672.

https://doi.org/10.1182/blood.V112.11.4672.4672

Published: 2008

Journal Articles

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Matti Aapro, Carsten Bokemeyer, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4715.

https://doi.org/10.1182/blood.V112.11.4715.4715

Published: 2008

Journal Articles

Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Matti Aapro, Carsten Bokemeyer, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4716.

https://doi.org/10.1182/blood.V112.11.4716.4716

Published: 2008

Journal Articles

Patient Nonadherence and Treatment Response to Imatinib in Patients with Chronic Myeloid Leukemia: Results from the ADAGIO Study

Lucien Noens, Marie-Anne van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachee, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald, Sabina De Geest, Tara Albrecht, Laurie Letvak, Ivo Abraham

Blood (2008) 112 (11): 2379.

https://doi.org/10.1182/blood.V112.11.2379.2379

Published: 2008

Journal Articles

Multimethod Clinical Assessment of Patterns and Prevalence of Nonadherence (NA) to Imatinib Treatment (IMRx) in Patients (Pts) with Chronic Myeloid Leukemia (CML): Results from the ADAGIO Study.

Marie-Anne van Lierde, Filipo Serra, Larissa De Rop, Eric Strobbe, Karen MacDonald, Stefaan Vancayzeele, Sabina De Geest, Laurie Letvak, Tara Albrecht, Ivo Abraham

Blood (2007) 110 (11): 5163.

https://doi.org/10.1182/blood.V110.11.5163.5163

Published: 2007

Journal Articles

Canonical Correlation Analysis (CCA) of Imatinib Treatment (ImRx) Nonadherence (NA) with Associated Patient Variables (APVs) in Chronic Myeloid Leukemia (CML) - Results from the ADAGIO Study.

Marie-Anne van Lierde, Larissa De Rop, Filipo Serra, Eric Strobbe, Karen MacDonald, Stefaan Vancayzeele, Sabina De Geest, Laurie Letvak, Tara Albrecht, Ivo Abraham

Blood (2007) 110 (11): 5164.

https://doi.org/10.1182/blood.V110.11.5164.5164

Published: 2007

NARROW

Comparative Cost-Efficiency Analysis of Trilaciclib, a Novel CDK4/6 Inhibitor, in the Prophylaxis of Chemotherapy-Induced Myelosuppression

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia: Meta-Analyses of Prevalence Rates By Measurement Method

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Patient Nonadherence and Treatment Response to Imatinib in Patients with Chronic Myeloid Leukemia: Results from the ADAGIO Study

Multimethod Clinical Assessment of Patterns and Prevalence of Nonadherence (NA) to Imatinib Treatment (IMRx) in Patients (Pts) with Chronic Myeloid Leukemia (CML): Results from the ADAGIO Study.

Canonical Correlation Analysis (CCA) of Imatinib Treatment (ImRx) Nonadherence (NA) with Associated Patient Variables (APVs) in Chronic Myeloid Leukemia (CML) - Results from the ADAGIO Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only